SANSURE BIOTECH INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.58 CNY | +2.65% |
|
-1.33% | -4.96% |
| Feb. 29 | Sansure Biotech's 2023 Profit Drops 81% as Revenue Slumps 84% | MT |
| Feb. 28 | Sansure Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Sansure Biotech Inc is a company mainly engaged in research and development, production and sales of diagnostic reagents and instruments. The Company's diagnostic reagent products are comprised of viral hepatitis series, reproductive tract infection and genetic series, pediatric infection series and nucleic acid blood screening series. The instrument products include automatic nucleic acid detection reaction system construction series and fluorescent polymerase chain reaction (PCR) monitoring and analysis software. The Company also provides related inspection services, including medical inspection and scientific research services which are provided for medical institutions.
Calendar
2024-04-22
- Q1 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.96% | 1.47B | |
| +2.19% | 13.22B | |
| -15.79% | 7.15B | |
| -6.48% | 4.97B | |
| -5.70% | 4.32B | |
| -2.82% | 4.13B | |
| -41.28% | 3.92B | |
| +7.49% | 2.62B | |
| -2.93% | 2.38B | |
| +0.16% | 1.72B |
- Stock Market
- Equities
- 688289 Stock
- News Sansure Biotech Inc.
- Sansure Biotech Gets Nod to Register HPV Test Kit; Shares Jump 3%
